Olmesartan Glenmark (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Glenmark, is a Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension and may be used in adults requiring blood pressure control. GNH USA supplies Olmesartan Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Essential hypertension: helps achieve target blood pressure and reduce cardiovascular risk. - Diastolic hypertension: provides effective reduction of diastolic pressure when systolic control is adequate. - Hypertension with chronic kidney disease: assists in slowing progression of renal impairment by lowering systemic pressure.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Cough

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Allergic skin reactions such as Stevens‑Johnson syndrome

When using Olmesartan medoxil, certain precautions should be observed to ensure safety and effectiveness.

- Monitor blood pressure: check regularly to confirm therapeutic response. - Assess renal function: evaluate kidney parameters before initiation and periodically thereafter. - Check electrolytes: especially potassium levels, to avoid hyperkalaemia. - Avoid use in pregnancy: drug is contraindicated in the second and third trimesters. - Review concomitant medications: assess for potential additive blood‑pressure‑lowering effects. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with aliskiren in diabetic patients: risk of renal impairment and hyperkalaemia. - Concomitant use with potassium‑saving diuretics or supplements: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - Lithium: may increase lithium levels, risking toxicity. - Dual renin‑angiotensin system blockade (e.g., ACE inhibitor): heightens risk of hypotension, renal dysfunction, and hyperkalaemia.